王者荣耀比分

Vertex Pharmaceuticals traded at $292.11 this Friday September 9th, increasing $3.12 or 1.08 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals gained 1.24 percent. Over the last 12 months, its price rose by 54.91 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 272.95 by the end of this quarter and at 250.04 in one year, according to 王者荣耀电竞(江西)积分排榜 global macro models projections and analysts expectations.

Stock Price
292.11
Daily Change
1.08%
Yearly
54.91%

Ok
王者荣耀电竞(江西)积分排榜 members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The 王者荣耀电竞(江西)积分排榜 Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AbbVie 141.42 0.90 0.64% 32.56%
Acadia Pharmaceuticals 17.38 -0.04 -0.23% 8.02%
Acorda Therapeutics 0.41 0.02 3.81% -91.13%
Agios Pharmaceuticals 34.14 0.14 0.41% -24.44%
Alnylam Pharmaceuticals 223.27 -3.03 -1.34% 17.79%
Amgen 247.69 2.24 0.91% 15.88%
Arrowhead Research 38.57 -0.60 -1.53% -39.73%
Biogen 211.84 3.86 1.86% -29.34%
Bluebird Bio 7.14 0.03 0.42% -60.07%
BioMarin Pharmaceutical 92.93 -0.08 -0.09% 19.17%
Bristol-Myers Squibb 70.16 0.78 1.12% 11.14%
Gilead Sciences 65.28 0.18 0.28% -8.04%
Intercept Pharmaceuticals 17.00 -0.13 -0.76% 16.04%
Incyte Corp 72.20 0.48 0.67% 1.52%
Insmed 24.83 0.11 0.45% -8.55%
Ionis Pharmaceuticals 46.84 2.57 5.81% 29.79%
J&J 165.71 0.32 0.19% -0.75%
Merck & Co 87.34 -0.08 -0.09% 18.91%
Moderna Inc 142.28 1.00 0.71% -68.34%
Neurocrine Biosciences 106.51 -0.17 -0.16% 10.10%
Novartis 79.36 0.58 0.74% 0.88%
Puma Biotechnology 2.74 0.18 7.03% -61.62%
Pfizer 47.84 0.76 1.61% 4.94%
PTC Therapeutics 53.64 -0.21 -0.39% 28.33%
Ultragenyx Pharmaceutical 49.24 1.51 3.16% -51.58%
Regeneron Pharmaceuticals 724.32 15.47 2.18% 11.35%
Roche Holding 324.25 0.40 0.12% -5.74%
Sanofi 81.20 0.64 0.79% -0.82%
Seattle Genetics 155.47 2.83 1.85% 2.61%
Sangamo BioSciences 5.70 -0.07 -1.21% -40.99%
Sarepta Therapeutics 118.44 -0.80 -0.67% 47.19%
United Therapeutics 223.48 -0.23 -0.10% 6.29%
Vertex Pharmaceuticals 292.11 3.12 1.08% 54.91%

Indexes Price Day Year
US500 4067 61.18 1.53% -8.77%
USND 12112 250.18 2.11% -19.87%
US400 2498 43.62 1.78% -7.02%
USNDX 12588 267.10 2.17% -18.47%

Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.